title: Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
abstract: BACKGROUND AND PURPOSE Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss; however, the noradrenergic system exhibits degeneration as well. Noradrenergic deficit in PD may be responsible for certain non-motor symptoms of the pathology, including psychiatric disorders and cognitive decline. The aim of this study was to generate a pre-motor rodent model of PD with noradrenergic denervation, and to assess whether treatment with exendin-4 (EX-4), a glucagon-like peptide 1 receptor agonist, could reverse impairment exhibited by our model. EXPERIMENTAL APPROACH We generated a model of PD utilizing N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine and 6-hydroxydopamine to create partial lesions of both the noradrenergic and dopaminergic systems respectively. We then assessed the validity of our model using an array of behavioural paradigms and biochemical techniques. Finally, we administered EX-4 over a 1 week period to determine therapeutic efficacy. KEY RESULTS Our model exhibits anhedonia and decreased object recognition as indicated by a decrease in sucrose preference, increased immobility in the forced swim test and reduced novel object exploration. Tissue and extracellular dopamine and noradrenaline were reduced in the frontal cortex and striatum. TH+ cell counts decreased in the locus coeruleus and substantia nigra. Treatment with EX-4 reversed behavioural impairment and restored extracellular/tissue levels of both dopamine and noradrenaline and TH+ cell counts. CONCLUSION AND IMPLICATIONS We conclude that early treatment with EX-4 may reverse certain neuropsychiatric dysfunction and restore dopamine and noradrenaline content.
authors: Department of Pharmacology, Faculty of Life Sciences, The School of Pharmacy, University College London, London, UK. n.rampersaud@ucl.ac.uk
authors: N
authors: N
authors: Rampersaud
authors: A
authors: A
authors: Harkavyi
authors: G
authors: G
authors: Giordano
authors: R
authors: R
authors: Lever
authors: J
authors: J
authors: Whitton
authors: Ps
authors: P
authors: Whitton
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001596:Benzylamines; D054022:Cerebrum / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D000077270:Exenatide; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001596:Benzylamines; D018696:Neuroprotective Agents; D010455:Peptides; D014688:Venoms; D016627:Oxidopamine; D000077270:Exenatide; C012102:DSP 4; D004298:Dopamine; D009638:Norepinephrine